Marit Sjo Lorentzen
Chief Operating Officer at ARCTICZYMES TECHNOLOGIES ASA
Net worth: 49 562 $ as of 2024-05-30
Marit Sjo Lorentzen active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Chief Operating Officer | - | - |
| Director/Board Member | - | - | |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Director/Board Member | - | - |
Career history of Marit Sjo Lorentzen
Training of Marit Sjo Lorentzen
| University of Tromso | Undergraduate Degree |
Statistics
International
| Norway | 4 |
Operational
| Director/Board Member | 2 |
| Chief Operating Officer | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
| Private companies | 1 |
|---|---|
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |
- Stock Market
- Insiders
- Marit Sjo Lorentzen
- Experience
